Passage Bio, Inc. (PASG) Q4 2021 Earnings Call

Investor webinar replay

Meeting Overview The meeting was a conference call discussing Passage Bio's financial and operational results for the fourth quarter and full year of 2021. Key topics included updates on pipeline programs, clinical trial advancements, and financial performance. Key Discussion Points - Overview of Passage Bio's evolution and growth in 2021. - Introduction of three programs into clinical trials and reporting of first in-human data. - Discussion of the GM1 gangliosidosis program and positive interim data. - Overview of the company's pipeline, including options for additional CNS programs. - Manufacturing and analytics capabilities and investments. - Financial performance and cash position at the end of 2021. Decisions Made - No explicit decisions recorded. Action Items & Next Steps - [Unassigned] : Continue to monitor and report interim safety and biomarker data for the GM1 program in the second half of 2022. - [Unassigned] : Submit an IND application for the MLD program in mid-2022. -...

Watch the replay

Replay transcript excerpt

[Speaker identities could not be resolved; generic labels used] [00:00] Speaker 1: Good morning and welcome to the Passage Bio 4th 0.25 and 4 year 2021 [00:04] Speaker 1: financial and operating results conference call. At this time, all participants are on a listen only mode. Following the formal remarks, we will open up the call for your questions. Please be advised that This call is being recorded at the company's request. [00:18] Speaker 1: At this time, I'd like to turn the conference over to Stuart Henderson, Vice President of Investor Relations and Strategic Finance. [00:25] Speaker 1: Stuart, please proceed. [00:32] Speaker 2: Stuart [00:39] Speaker 3: Henderson Thank you, Operator. Thank you, operator. [00:40] Speaker 3: This morning we issued a press release that outlines the topics we plan to discuss today. This release is available on the PassageBio website under the Press Releases and Statements section of Investors in News. [00:52] Speaker 3: On today's call, Bruce Goldsmith, President and Chief Executive Officer, will review our recent and 2021 [00:58] Speaker 3: business highlights. [00:59] Speaker 3: Eliseo Salinas, our Chief Research and Development Officer, will review our pipeline programs, including the GM1 data recently presented at the World Symposium, [01:08] Speaker 3: and Simona King, our Chief Financial Officer, will review our 4th 0.25 and full year 2021 financial results. [01:15] Speaker 3: Before we begin, please note that today's call may include a number of forward-looking statements, including but not limited to comments on our expectations about timing and execution of anticipated milestones, [01:27] Speaker 3: including the initiation of clinical trials and the availability of data from such trials, [01:32] Speaker 3: our expectatio...